Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea
Open Access
- 23 July 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (5) , 808-820
Abstract
Summary: Background: In primary bile acid diarrhoea, feedback by farnesoid X receptor (FXR) and fibroblast growth hormone 19 (FGF19) on hepatic bile acid production is impaired.Aims: To evaluate the safety, mechanisms and efficacy of negative feedback by FXR activation with tropifexor, a non‐bile acid FXR agonist, in patients with primary bile acid diarrhoea.Methods: In this double‐blind, multicentre, randomised, cross‐over study, patients received tropifexor 60 µg or placebo once daily for 14 days in each of two treatment periods. Primary objectives included tropifexor safety and tolerability, and on stool frequency and form. Other assessments included pharmacokinetic and pharmacodynamic measures, biochemical markers and gastrointestinal transit.Results: Twenty patients (tropifexor 60 µg/placebo [N = 10]; placebo/tropifexor 60 µg [N = 10]) were enrolled. Adverse event rates were lower with tropifexor vs placebo (52.9% vs 73.7%). No patient had pruritus during tropifexor intake. There were no significant differences in stool frequency, stool form or loperamide use between treatments. Tropifexor increased FGF19 and decreased 7α‐hydroxy‐4‐cholesten‐3‐one (C4) levels for up to 8 h. Plasma tropifexor concentrations peaked at 5 hours post‐dose on days 1 and 12. At day 12, tropifexor caused reduction in peak total bile acid concentration (33%, P = 0.032) and exposure (36%, P = 0.005). Moreover, tropifexor showed a significant increase in ascending colon half‐emptying time (P = 0.036).Conclusions: Tropifexor 60 µg once daily had acceptable safety and tolerability. Changes in FGF19 and C4 showed effective target engagement; however, higher doses may be required to observe stool frequency changes. Slowing of ascending colon emptying suggests therapeutic potential of tropifexor in patients with primary bile acid diarrhoea.ClinicalTrials.gov number: NCT02713243.Keywords
Funding Information
- Novartis Institutes for BioMedical Research
This publication has 35 references indexed in Scilit:
- Advances in understanding of bile acid diarrheaExpert Review of Gastroenterology & Hepatology, 2013
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid DiarrheaClinical and Translational Gastroenterology, 2012
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXRNature Reviews Molecular Cell Biology, 2012
- How to Interpret a Functional or Motility Test - Colon Transit StudyJournal of Neurogastroenterology and Motility, 2012
- A Klothoβ Variant Mediates Protein Stability and Associates With Colon Transit in Irritable Bowel Syndrome With DiarrheaGastroenterology, 2011
- A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid BiosynthesisClinical Gastroenterology and Hepatology, 2009
- Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2009
- Review: The treatment of irritable bowel syndromeTherapeutic Advances in Gastroenterology, 2009
- Colonic Secretion of Water and Electrolytes Induced by Bile Acids: Perfusion Studies in ManJournal of Clinical Investigation, 1971